Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abacavir once-daily versus twice-daily pharmacokinetic crossover study in adults with HIV infection
2004-000754-24Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of abacavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by GSK. Primary endpoints: Intracellular carbovir triphosphate AUC(0-24), Intracellular carbovir triphosphate Cmax and 2 more. Started Jun 2005; status: completed.
02
Drugs
abacavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-000754-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000754-24.